Portal de Periódicos da CAPES

A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study

2009; Elsevier BV; Volume: 125; Issue: 4 Linguagem: Inglês

10.1016/j.thromres.2009.06.016

1879-2472

Tullio Palmerini, Chiara Barozzi, Luciana Tomasi, Diego Sangiorgi, Antonío Marzocchi, Stefano De Servi, Paolo Ortolani, Maria Letizia Bacchi Reggiani, Laura Alessi, Giulia Lauria, M. Bassi, Angelo Branzi,

Venous Thromboembolism Diagnosis and Management

Introduction The antiplatelet effect of standard or increased clopidogrel doses in patients with ST- segment elevation acute myocardial infarction (STEMI) has never been studied. In this study we compared the antiplatelet effect of a 75 mg daily maintenance dose of clopidogrel with 150 mg in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Materials and methods Fifty-four patients with STEMI undergoing PCI were randomly allocated to receive either 75 mg/day clopidogrel (group 1) or 150 mg/day (group 2) for 1 month. Platelet function, measured by 5 different assays, was determined at 3 time points: 38±8 hours after the procedure, 1 week and 1 month after randomization. Results In group 1, mean ± SD platelet reactivity index (PRI) measured with the VASP assay was 57.7±15.7% and 46.9±15.7% at 1 week and 1 month, respectively, compared to 38.8±15.7% and 34.9±12.6% in group 2 (p=0.0001). Same results were observed for light transmittance aggregometry, whole blood aggregometry and VerifyNow, but not for thromboelastometry. In contrast to what may be expected, the 75 mg daily maintenance dose took longer than 1-week to provide the full clopidogrel antiplatelet effect. Furthermore, patients in group 2 had a nearly 50% reduction in C-reactive protein levels both at 1 week and 1 month. Conclusion In patients with STEMI and poor responsiveness to clopidogrel a 150 mg daily maintenance dose of clopidogrel is associated with a significant reduction of platelet aggregation and a trend towards reduced inflammation.